Sam Miller

Cooley advised Vera Therapeutics, a clinical-stage biotechnology company, on its $115 million follow-on offering of common stock. Partners Jodie Bourdet and Kristin VanderPas led the Cooley team.

Cooley advised Vera Therapeutics on its $86 million follow-on offering of 55,742,026 shares of Class A common stock at a price to the public of $15.00 per share. Vera is a late-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunological diseases. Jodie Bourdet, Brett White and Alexa Ekman led the Cooley team.

Cooley advised Motive, a leading automated operations platform for the physical economy, on its $150 million Series F financing round, bringing the company’s valuation to $2.85 billion. Lawyers Rachel Burns and Rachel Proffitt led the Cooley team advising Motive.

Cooley advised Checkr, an HR technology company powering the future of work, on its $250 million Series E financing round, catapulting its valuation to $4.6 billion. Partner Calise Cheng led the Cooley team advising Checkr.

Cooley advised Vera Therapeutics on its $47.85 million initial public offering of 4,350,000 shares of class A common stock. Vera Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol VERA, is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Partners Jodie Bourdet and Carlton Fleming led the Cooley team.